Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study

BACKGROUND: Major depressive disorder (MDD) is a global health concern. This study examined the efficacy, safety and tolerability of an extended-release (ER) formulation of levomilnacipran, an antidepressant approved for the treatment of MDD in adults. METHODS: This 10-week (1-week placebo run-in pe...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bakish, David, Bose, Anjana, Gommoll, Carl, Chen, Changzheng, Nunez, Rene, Greenberg, William M., Liebowitz, Michael, Khan, Arif
Médium: Artigo
Jazyk:Inglês
Vydáno: Canadian Medical Association 2014
Témata:
Research Papers
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868664/
https://ncbi.nlm.nih.gov/pubmed/24144196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/jpn.130040
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky